Phase I and pharmacologic study of topotecan in patients with impaired renal function

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S O'ReillyL B Grochow

Abstract

To determine the toxicities, pharmacokinetics, and recommended doses of the topoisomerase I inhibitor, topotecan, in patients with varying degrees of renal excretory dysfunction. Fourteen patients with normal renal function [creatinine clearance (CrCl) > or = 60 mL/min] and 28 patients with varying degrees of renal dysfunction were treated with topotecan 0.4 to 2.0 mg/m2/d as a 30-minute infusion for 5 consecutive days every 3 weeks. Plasma and urine samples were obtained to determine the disposition of topotecan. In patients with mild renal dysfunction (CrCl = 40 to 59 mL/min), dose-limiting hematologic toxicity was observed in three of eight patients receiving topotecan 1.0 mg/m2/d and in two of five patients receiving topotecan 1.5 mg/m2/d. In patients with moderate renal dysfunction (CrCl = 20 to 39 mL/min), dose-limiting hematologic toxicity was observed in three of eight patients who received topotecan 0.5 mg/m2/d, and in two of four patients receiving topotecan 1.0 mg/m2/d; these events were more frequently observed in extensively pretreated patients. Pharmacokinetic analyses showed significant correlations between CrCl and the plasma clearance of both total topotecan [Spearman's correlation coefficient (r2) = 0.65, P = ...Continue Reading

Citations

Sep 28, 1998·Cancer Chemotherapy and Pharmacology·L Iyer, M J Ratain
Jun 17, 2000·American Journal of Clinical Oncology·C W RyanM J Ratain
Dec 19, 2002·Journal of the National Cancer Institute·Sharyn D BakerAlex Sparreboom
Mar 14, 2003·Anti-cancer Drugs·Walter J LoosAlex Sparreboom
Sep 28, 1998·Cancer Chemotherapy and Pharmacology·M J Egorin
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M GalloS D Baker
May 5, 2001·Expert Opinion on Pharmacotherapy·B Arun, E P Frenkel
May 26, 2006·Expert Opinion on Pharmacotherapy·D PectasidesT Economopoulos
Oct 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R ParkKatherine K Matthay
Feb 14, 2015·British Journal of Clinical Pharmacology·Lot A DevrieseJan H M Schellens
May 2, 2020·World Journal of Clinical Oncology·Maria Luísa Cordeiro SantosFabrício Freire de Melo
Sep 27, 2002·The Oncologist·Charles J Dunton
Jan 7, 1999·The Annals of Pharmacotherapy·R J Cersosimo
Dec 18, 2001·The Oncologist·L BomgaarsS M Blaney
Jan 30, 2007·Expert Opinion on Pharmacotherapy·Leslie M Randall-Whitis, Bradley J Monk
Mar 10, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Jörg T Hartmann, Hans-Peter Lipp
Feb 21, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Y F LiJ J Kavanagh
Sep 3, 2004·Journal of Pediatric Hematology/oncology·Lisa C IaconoClinton F Stewart
Feb 1, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K F TamH Y S Ngan
Jul 28, 2001·American Journal of Clinical Oncology·L BekeleA A Adjei
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyR L De Jager
Aug 22, 2018·Cancer Chemotherapy and Pharmacology·Stephen V LiuEdward M Newman
Dec 29, 2000·Anti-cancer Drugs·W J LoosA Sparreboom
Dec 6, 2005·Cancer Chemotherapy and Pharmacology·Jean-Pierre DelordEtienne Chatelut
Oct 31, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·L V IvanovaD Proppe

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.